Cannara Biotech Inc. (LOVE.TO) continues to navigate the cannabis landscape with notable performance and strategic moves.
This week, Cannara Biotech Inc. saw a slight increase in its stock price, reflecting ongoing developments in its business operations. The company is focused on expanding its market presence and improving profitability, attracting attention from investors in the cannabis sector.
Advertisement
Cannara Biotech Inc.
LOVE.TO
LOVE.TO
Cannara Biotech Inc.
WealthAwesomeAdvertisement
Market cap
$193.61M
P/E
17.8x
52W high
$2.07
52W low
$1.55
1W change
+2.59%
Beta
0.35
Analyst Price Targets
Based on analyst covering LOVE
Wall Street analysts forecast LOVE stock price to rise 70.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.38
+70.5% Upside
Current Price
C$1.98
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LOVE's historical volatility
30-Day Vol
38.0%
Annualized
90-Day Vol
36.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$2.37
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.10 | C$1.84 – C$2.40 |
| 60 trading days | C$2.23 | C$1.85 – C$2.68 |
| 90 trading days | C$2.37 | C$1.89 – C$2.97 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Cannara's recent financial results and strategic initiatives may position it well for future growth, but investors should stay mindful of the inherent risks in the cannabis industry.
Cannara Biotech Reports Record Q3 Revenues of $31.8 Million
The company achieved a gross profit of $13.4 million and an adjusted EBITDA of $8.5 million, indicating strong operational performance.
Bull case
Cannara's record Q3 revenues and exclusive rights to innovative technology demonstrate its commitment to growth and profitability.
Bear case
Despite these positive developments, the cannabis market remains volatile, and Cannara's stock performance could be affected by broader industry challenges.
Price Action Overview
Cannara Biotech Inc. (LOVE.TO) closed at C$1.98, marking a 1.02% increase for the day. Over the past week, the stock has gained 2.59%, contributing to a year-to-date rise of 7.61%. This performance reflects the company's ongoing efforts to establish a strong foothold in the competitive cannabis market.
Recent Company Developments
Advertisement
Cannara has made headlines with its record Q3 revenues, reporting net revenues of $31.8 million and a gross profit of $13.4 million. The company also secured exclusive Canadian rights to Blue River's Ampersand™ live rosin infusion technology, aiming to enhance its product offerings. Additionally, Cannara announced a normal course issuer bid to repurchase up to 1,975,642 common shares, indicating confidence in its stock value.
Technical Picture
Cannara's stock is currently trading above its 50-day and 200-day moving averages, which are both at C$1.78, representing a 10.9% and 11.3% premium to the current price, respectively. The stock has a 52-week range of C$1.55 to C$2.07, indicating it is trading at approximately 83% of its range. With a beta of 0.35, Cannara's stock has been less volatile compared to the broader market. However, recent trading volume has been low, with only 4,040 shares changing hands, significantly below the 20-day average volume of 66,045 shares.
Insider Activity
No recent insider activity has been reported for Cannara Biotech Inc., suggesting that there have not been any significant insider transactions in the recent period.
Conclusion
As Cannara Biotech Inc. continues to report positive financial results and expand its market offerings, investors may find opportunities in its growth strategy. However, the cannabis sector remains uncertain, and potential investors should conduct thorough research and consider the risks involved. Last close: C$1.98, 1D: +1.02%.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
